Global Tuberculosis Report 2017

The World Health Organization (WHO) has set a target to end the TB epidemic by 2030, with a focus on reducing the number of new TB cases and deaths. The End TB Strategy outlines key strategies to achieve this goal, including improving access to quality TB diagnosis and treatment, strengthening health systems, and promoting community engagement. TB disease burden is a significant public health concern, with an estimated 10 million new cases and 1.6 million deaths in 2016. The majority of TB cases occur in low- and middle-income countries, where access to quality healthcare is limited. The WHO has developed a global TB database to track TB cases and deaths, which provides valuable information for TB control efforts. Diagnosis and treatment of TB, HIV-associated TB, and drug-resistant TB are critical components of TB control. The WHO recommends the use of rapid diagnostic tests, such as the Xpert MTB/RIF assay, to detect TB and detect rifampicin resistance. Treatment of TB typically involves a combination of antibiotics, including isoniazid, rifampicin, and pyrazinamide, for a minimum of 6 months. For drug-resistant TB, treatment is more complex and may involve the use of second-line antibiotics. TB prevention services are essential to prevent the spread of TB. The WHO recommends the use of the Bacille Calmette-Guérin (BCG) vaccine to prevent TB in children, and the use of isoniazid preventive therapy (INH-PT) to prevent TB in people living with HIV. Contact tracing and contact tracing and treatment of latent TB infection (LTBI) are also critical components of TB prevention. Financing for TB prevention, diagnosis, and treatment is a significant challenge, particularly in low- and middle-income countries. The WHO estimates that an additional $2 billion is needed annually to achieve the End TB Strategy. The Global Fund to Fight AIDS, Tuberculosis and Malaria has provided significant funding for TB control efforts, and the WHO has developed a financing framework to guide national TB programs. Universal health coverage, social protection, and social determinants are critical components of TB control. The WHO recommends the use of universal health coverage to ensure access to quality healthcare, including TB diagnosis and treatment. Social protection programs, such as cash transfers and health insurance, can also help to reduce poverty and improve health outcomes. Social determinants, such as housing and sanitation, can also contribute to the spread of TB. TB research and development is essential to improve TB diagnosis and treatment. The WHO has developed a global TB research and development strategy, which includes the development of new diagnostic tests, treatments, and treatments for drug-resistant TB. The WHO has also established a TB research and development partnership to facilitate collaboration and coordination among researchers and stakeholders. The WHO has developed a global TB database to track TB cases and deaths, which provides valuable information for TB control efforts. The database includes data on TB cases and deaths, as well as information on TB diagnosis and treatment. The WHO has also developed a country profile for each country, which provides information on TB burden, TB cases and deaths, and TB control efforts. TB control efforts require a comprehensive approach, including improving access to quality TB diagnosis and treatment, strengthening